• Consensus Rating: Buy
  • Consensus Price Target: $260.67
  • Forecasted Upside: 20.44 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$216.43
▲ +0.71 (0.33%)

This chart shows the closing price for RMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ResMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RMD

Analyst Price Target is $260.67
▲ +20.44% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for ResMed in the last 3 months. The average price target is $260.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 20.44% upside from the last price of $216.43.

This chart shows the closing price for RMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 polled investment analysts is to buy stock in ResMed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/6/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$233.00 ➝ $244.00Low
4/5/2022Wolfe ResearchInitiated CoverageOutperform$280.00Low
1/31/2022CitigroupUpgradeNeutral ➝ BuyHigh
1/30/2022The Goldman Sachs GroupUpgradeNeutral ➝ BuyHigh
1/28/2022Robert W. BairdLower Price Target$300.00 ➝ $280.00High
1/28/2022Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$234.00 ➝ $241.00High
1/24/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$260.00 ➝ $270.00High
1/24/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$239.00 ➝ $250.00Medium
1/13/2022Robert W. BairdUpgradeNeutral ➝ Outperform$270.00 ➝ $300.00High
1/13/2022Royal Bank of CanadaBoost Price TargetUnderperform$227.00 ➝ $234.00High
12/6/2021MacquarieUpgradeNeutral ➝ OutperformHigh
10/29/2021Royal Bank of CanadaLower Price TargetUnderperform$233.00 ➝ $227.00Medium
10/22/2021CLSAUpgradeUnderperform ➝ OutperformMedium
8/9/2021CLSAUpgradeSell ➝ UnderperformMedium
8/9/2021Needham & Company LLCReiterated RatingHoldLow
8/2/2021CLSADowngradeOutperform ➝ SellLow
8/2/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
7/28/2021Jefferies Financial GroupUpgradeUnderperform ➝ Hold$170.00 ➝ $240.00Medium
7/27/2021Royal Bank of CanadaBoost Price TargetUnderperform$223.00 ➝ $238.00High
7/26/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$245.00 ➝ $246.00Low
7/13/2021Royal Bank of CanadaInitiated CoverageUnderperform$223.00Low
6/28/2021CitigroupDowngradeBuy ➝ NeutralLow
6/22/2021MacquarieUpgradeNeutral ➝ OutperformLow
6/21/2021Robert W. BairdInitiated CoverageNeutral$240.00Low
6/21/2021Needham & Company LLCBoost Price TargetPositive ➝ Buy$229.00 ➝ $267.00Low
6/16/2021Bank of AmericaDowngradeNeutral ➝ Underperform$216.00 ➝ $221.00High
6/15/2021OppenheimerBoost Price TargetOutperform$240.00 ➝ $270.00High
6/14/2021Needham & Company LLCInitiated CoverageBuy$229.00High
6/9/2021CLSAUpgradeSell ➝ OutperformLow
5/21/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$206.00 ➝ $219.00Low
5/11/2021CitigroupUpgradeNeutral ➝ BuyLow
4/30/2021CitigroupDowngradeBuy ➝ NeutralHigh
3/16/2021Needham & Company LLCUpgradeHold ➝ Buy$229.00Low
1/29/2021Needham & Company LLCReiterated RatingHoldHigh
11/2/2020UBS GroupUpgradeNeutral ➝ Buy$210.00High
10/30/2020Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
10/30/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$165.00Medium
10/27/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$186.00High
8/6/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightMedium
8/6/2020OppenheimerBoost Price Target$200.00 ➝ $210.00Medium
8/6/2020The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
8/6/2020Needham & Company LLCReiterated RatingHoldHigh
8/5/2020OppenheimerInitiated CoverageBuy$212.00High
8/3/2020Bank of AmericaDowngradeBuy ➝ UnderperformLow
6/17/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$176.00Low
5/1/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
4/30/2020Needham & Company LLCInitiated CoverageHoldHigh
4/30/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00High
3/26/2020Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
3/24/2020William BlairReiterated RatingBuyLow
2/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$165.00Low
2/3/2020CLSAInitiated CoverageUnderperformHigh
1/31/2020UBS GroupDowngradeBuy ➝ Neutral$174.00High
1/9/2020OppenheimerInitiated CoverageHoldLow
11/22/2019KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
10/25/2019Needham & Company LLCReiterated RatingHoldHigh
10/18/2019Needham & Company LLCReiterated RatingHoldLow
7/29/2019UBS GroupUpgradeNeutral ➝ Buy$122.00 ➝ $140.00Medium
7/29/2019The Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
7/16/2019UBS GroupDowngradeBuy ➝ NeutralLow
5/6/2019UBS GroupUpgradeNeutral ➝ Buy$109.00 ➝ $119.00Low
4/18/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$95.00Low
3/20/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
1/28/2019BMO Capital MarketsLower Price TargetOutperform ➝ Positive$120.00High
1/25/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$99.60High
1/25/2019The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
1/23/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
12/10/2018BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$109.00 ➝ $127.00Medium
10/26/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$107.00 ➝ $109.00N/A
10/26/2018Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
7/1/2018The Goldman Sachs GroupInitiated CoverageBuyLow
4/24/2018UBS GroupDowngradeBuy ➝ NeutralMedium
4/16/2018William BlairReiterated RatingOutperformLow
4/4/2018CitigroupDowngradeBuy ➝ NeutralMedium
3/7/2018Needham & Company LLCReiterated RatingHoldMedium
1/23/2018Northland SecuritiesUpgradeUnder Perform ➝ Market PerformHigh
1/23/2018MacquarieDowngradeNeutral ➝ SellHigh
1/23/2018BMO Capital MarketsBoost Price TargetMarket Perform$90.00High
1/23/2018Needham & Company LLCUpgradeUnderperform ➝ HoldHigh
12/12/2017BMO Capital MarketsBoost Price TargetMarket Perform$82.00Low
10/30/2017JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 ➝ $73.00N/A
10/27/2017BMO Capital MarketsBoost Price TargetMarket Perform$70.00 ➝ $74.00N/A
10/27/2017BarclaysBoost Price TargetUnderweight$68.00 ➝ $70.00N/A
10/27/2017Northland SecuritiesReiterated RatingSell$55.00N/A
10/27/2017Needham & Company LLCReiterated RatingSellN/A
10/12/2017Jefferies Financial GroupReiterated RatingSell$56.00N/A
9/25/2017BarclaysBoost Price TargetUnderweight ➝ Underweight$65.00 ➝ $68.00Low
9/8/2017Needham & Company LLCReiterated RatingSellLow
8/8/2017Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
8/2/2017BMO Capital MarketsBoost Price TargetMarket Perform$61.00 ➝ $70.00Medium
8/2/2017Needham & Company LLCReiterated RatingSellHigh
8/2/2017CitigroupUpgradeNeutral ➝ BuyHigh
8/2/2017Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
8/2/2017Bank of AmericaDowngradeBuy ➝ NeutralHigh
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/8/2021
  • 4 very positive mentions
  • 11 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
1/7/2022
  • 5 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
2/6/2022
  • 2 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/8/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2022
  • 3 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/6/2022
  • 7 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 7 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
ResMed logo
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $216.43
Low: $210.30
High: $216.59

50 Day Range

MA: $203.81
Low: $191.41
High: $216.43

52 Week Range

Now: $216.43
Low: $189.40
High: $301.34

Volume

504,589 shs

Average Volume

604,655 shs

Market Capitalization

$31.66 billion

P/E Ratio

40.76

Dividend Yield

0.78%

Beta

0.42

Frequently Asked Questions

What sell-side analysts currently cover shares of ResMed?

The following Wall Street sell-side analysts have issued stock ratings on ResMed in the last year: Bank of America Co., Citigroup Inc., CLSA, Jefferies Financial Group Inc., JPMorgan Chase & Co., Macquarie, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, StockNews.com, The Goldman Sachs Group, Inc., and Wolfe Research.
View the latest analyst ratings for RMD.

What is the current price target for ResMed?

0 Wall Street analysts have set twelve-month price targets for ResMed in the last year. Their average twelve-month price target is $260.67, suggesting a possible upside of 20.4%.
View the latest price targets for RMD.

What is the current consensus analyst rating for ResMed?

ResMed currently has 3 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RMD will outperform the market and that investors should add to their positions of ResMed.
View the latest ratings for RMD.

How do I contact ResMed's investor relations team?

ResMed's physical mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider's listed phone number is (858) 836-5000 and its investor relations email address is [email protected] The official website for ResMed is www.resmed.com. Learn More about contacing ResMed investor relations.